This study is accepting new patients by invitation only

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

a study on Anemia

Summary

Eligibility
for people ages 18-100 (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

The primary objective of this study is:

• To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Keywords

Warm Antibody Autoimmune Hemolytic Anemia, wAIHA, Warm Autoimmune Hemolytic Anemia, Anemia, Hemolytic Anemia, Anemia, Hemolytic, Autoimmune, Hemolysis, Fostamatinib disodium, Fostamatinib

Eligibility

You can join if…

Open to people ages 18-100

  1. Subject must be willing and able to give written informed consent by signing an IRB approved Informed Consent Form prior to undergoing any study-specific procedures.
  2. Subject must have completed all 24 weeks of participation in the study C-935788-057.

You CAN'T join if...

1. Any subject who discontinued participation in Study C-935788-057 prior to Week 24.

Locations

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance California 90502 United States
  • University of Southern California - Janice and Robert Hall Clinical Trials Biospecimen Laboratory
    Los Angeles California 90033 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Rigel Pharmaceuticals
ID
NCT04138927
Phase
Phase 3 Anemia Research Study
Study Type
Interventional
Participants
Expecting 90 study participants
Last Updated